| 邓倩曦,邹龙.莫沙必利、舒必利及坦度螺酮联合治疗以腹胀为主躯体化障碍 43例疗效观察[J].安徽医药,2020,24(3):576-579. |
| 莫沙必利、舒必利及坦度螺酮联合治疗以腹胀为主躯体化障碍 43例疗效观察 |
| Efficacy of mosapride plus sulpiride and tandospirone in the treatment of 43 cases of somatization disorders with complain of abdominal distension |
| |
| DOI：10.3969/j.issn.1009?6469.2020.03.039 |
| 中文关键词: 躯体型障碍 莫沙必利 舒必利 坦度螺酮 腹胀 |
| 英文关键词: Somatoform disorders Mosapride Sulpiride Tandospirone Abdominal distension |
| 基金项目: |
|
| 摘要点击次数: 2240 |
| 全文下载次数: 1035 |
| 中文摘要: |
| 目的探讨在治疗以腹胀为主要症状的躯体化障碍中应用莫沙必利、舒必利及坦度螺酮的疗效及安全性。方法选取 2017年7—12月期间四川省精神卫生中心接诊的 83例以腹胀症状为主要表现的躯体化障碍病人，将入组病人按照随机数字表法分为对照组(40例)与研究组(43例)对照组给予莫沙必利治疗(10 mg每天 3次)，研究组在此基础上联合舒必利(0.1 g每天两次)和坦度螺酮(10 mg每天 3次)。服药时，间 3个月，随访时间 6个月，比较治疗前后两组病人各系统症状总积分、临床疗效(症状缓解有效率)及治疗期间的不良反应。结果治疗前两组病人各系统症状总积分差异无统计学意义(t＝0.547，P＝0.586)治疗后对照组各系统症状总积分由治疗前的(9.97±1.47)分降低为(6.13±0.61)分，研究组各系统症状总积分由治疗前的(9.80±1.36)，分降低为(3.40±0.58)分，治疗后对照组及研究组的各系统症状总积分与治疗前的差异有统计学意义(P＜0.05)研究组显著低于对照组( P＜0.05)；研究组临床治疗总有效率 93.02%，显著高于对照组 77.50%(P＜0.05)；对照组治疗期间不良反，应发生率为 7.50%，研究组不良反应发生率为 9.30%，差异无统计学意义(χ2＝0.000，P＝1.000)。结论莫沙必利、舒必利及坦度螺酮联合治疗以腹胀为主要表现的躯体化障碍可显著改善病人症状、提升治疗效果，且不会导致不良反应作用的明显增多，值得临床推广应用。 |
| 英文摘要: |
| Objective To explore the efficacy and safety of applying mosapride，sulpiride and tandospirone to the treatment of so? matization disorders with abdominal distension as the cardinal symptom.Methods From July 2017 to December 2017，83 patientswith somatization disorders whose main symptoms were abdominal distension were selected from the Sichuan Mental Health Center.The patients were randomly divided into the control group(40 cases)and the study group(43 cases)according to random num? bers.The control group was given mosapride(10 mg 3 times a day)，and the study group was combined with sulpiride(0.1 g twice a day)and tantrolone(10mg 3 timesa day).The medication time was 3 months，and the follow?up time was 6 months.The total scores of systemic symptoms，clinical efficacy(effectiveness of symptom relief)and adverse reactions during treatment were com? pared between the two groups before and after treatment.Results There was no significant difference in the total scores of system? ic symptoms between the two groups before treatment(t＝0.547，P＝0.586).After treatment，the total scores of systemic symptoms in the control group decreased from(9.97±1.47)before treatment to(6.13±0.61).The total systemic symptom score decreased from(9.80±1.36)before treatment to(3.40±0.58).The total system symptom scores of the study group before treatment was significantly lower than that in the control group(P＜0.05)； the total effective rate of clinical treatment in the study group was 93.02%，which was significantly higher than that in the control group of 77.50%(P＜0.05)； the incidence of adverse reactions during the treat? ment period in the control group was 7.50%，and the incidence of adverse reactions in the study group was 9.30%，the difference is not significant(χ2＝0.000，P＝1.000).Conclusion A combined use of mosapride，sulpiride and tandospirone to treat the somatiza?tion disorder with abdominal distension as a cardinal symptom can significantly improve the patient’s symptoms and enhance cura? tive effect，and will not lead to a significant increase of adverse reactions，deserving a clinical popularization and application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
